Prescription medicine
Atazanavir and cobicistat Brand names: Evotaz
Atazanavir and cobicistat (Evotaz) is a prescription medicine with an FDA approval on record since 2015. No generic is listed; pharmacies paid $52.05 per Evotaz 300 mg-150 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- A presentation discontinued
Check it at the source: the atazanavir and cobicistat FDA label on DailyMed (effective May 12, 2025, E.R. Squibb & Sons, L.L.C.); the NDA 206353 record on Drugs@FDA; every atazanavir and cobicistat label on DailyMed.
Highlights of the record
FDA label of May 12, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg.
Forms and strengths
- 300 mg / 150 mg
Tablet.
On the market
- Earliest approval on file
- January 29, 2015 Evotaz, Bristol; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- October 6, 2032 Evotaz tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $52.05 per tablet Evotaz 300 mg-150 mg tablet
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 245 through July 30, 2026
What is atazanavir and cobicistat used for?
From the label: indications and usageEVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. […]
Conditions named in the indications of atazanavir and cobicistat's FDA labels, with every medicine labeled for each:
From other atazanavir and cobicistat labelsHIV: Indications EVOTAZ ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in the following populations [see Dosage and Administration (2.2 , 2.3) ]:
FDA pharmacologic class: Cytochrome P450 3A Inhibitor and Protease Inhibitor.
Source: FDA drug label (EVOTAZ), NDA206353 (Bristol), as published by E.R. Squibb & Sons, L.L.C., effective May 12, 2025 (SPL set 83db29d7-5d85-49d6-8cb6-740473365cf8), via openFDA; the full label on DailyMed
Is there a generic for atazanavir and cobicistat (Evotaz)?
No generic atazanavir and cobicistat is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Evotaz tablets: the compound patent runs to September 3, 2029, and the last listed entry to October 6, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2032 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for atazanavir and cobicistat (Evotaz)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $52.05 per Evotaz 300 mg-150 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Evotaz 300 mg-150 mg tablet (brand)
$52.08
$51.94
April 2024October 2026
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Evotaz 300 mg-150 mg tablet | Brand | $52.05 per tablet | $1,561.44 | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is atazanavir and cobicistat in shortage?
No atazanavir and cobicistat presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated November 3, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11) | Bristol Myers Squibb Co. | To Be Discontinued | November 3, 2025 |
Every atazanavir and cobicistat presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the atazanavir and cobicistat label say about other medicines?
The atazanavir and cobicistat label names 121 other medicines in its interaction, contraindication or warning sections. The labels of 3 other medicines name atazanavir and cobicistat. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Alfuzosin | contraindications | Drug Class: Alpha 1-adrenoreceptor antagonist; Drugs within class that are contraindicated with EVOTAZ: alfuzosin |
| Amiodarone | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; Effect b on Concentration: ↑ other antiarrhythmics ↑ digoxin; Clinical Comment: Clinical monitoring is recommended upon coadministration with antiarrhythmics. … |
| Amitriptyline | drug interactions | Concomitant Drug Class/Specific Drugs: Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, desipramine, imipramine, nortriptyline); Effect b on Concentration: ↑ TCAs |
| Amlodipine | drug interactions | Concomitant Drug Class/Specific Drugs: Calcium channel blockers: (e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil); Effect b on Concentration: ↑ calcium channel blocker; Clinical Comment: Clinical monitoring is recommended for coadministration with calcium channel blockers metabolized by CYP3A. … |
| Apalutamide | contraindications | Drug Class: Antineoplastics; Drugs within class that are contraindicated with EVOTAZ: apalutamide, encorafenib, irinotecan, ivosidenib |
| Apixaban | drug interactions | Concomitant Drug Class/Specific Drugs: Anticoagulants: Direct-acting oral anticoagulants (DOACs) apixaban; Effect b on Concentration: ↑ apixaban; Clinical Comment: Due to potentially increased bleeding risk, dosing recommendations for coadministration of apixaban with EVOTAZ depends on the apixaban dose. … |
| Atorvastatin | drug interactions | Concomitant Drug Class/Specific Drugs: Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Effect b on Concentration: ↑ HMG-CoA reductase inhibitors; Clinical Comment: Coadministration of EVOTAZ with atorvastatin is not recommended. … |
| Avanafil | drug interactions | Concomitant Drug Class/Specific Drugs: Phosphodiesterase-5 (PDE-5) inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect b on Concentration: ↑ PDE-5 inhibitors; Clinical Comment: Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH): Coadministration of EVOTAZ with sildenafil is contraindicated … |
| Beclomethasone | drug interactions | … can increase the risk for Cushing’s syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone, prednisone, and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. |
| Betamethasone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↑ corticosteroids; … |
| Bosentan | drug interactions | Concomitant Drug Class/Specific Drugs: Endothelin receptor antagonists: bosentan; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↑ bosentan; Clinical Comment: Initiation of bosentan in patients taking EVOTAZ: For patients who have been receiving EVOTAZ for at least 10 days, start bosentan at 62.5 mg once daily … |
| Budesonide | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↑ corticosteroids; … |
| Buprenorphine | drug interactions | A dose adjustment for buprenorphine, buprenorphine/naloxone or methadone may be needed. |
| Buprenorphine and naloxone | drug interactions | A dose adjustment for buprenorphine, buprenorphine/naloxone or methadone may be needed. |
Every other medicine the atazanavir and cobicistat label names
| Medicine named | Section | What the label says |
|---|---|---|
| Carbamazepine | contraindications | Drug Class: Anticonvulsants; Drugs within class that are contraindicated with EVOTAZ: carbamazepine, phenobarbital, phenytoin |
| Carvedilol | drug interactions | Concomitant Drug Class/Specific Drugs: Beta-Blockers: (e.g., metoprolol, carvedilol, timolol); Effect b on Concentration: ↔ atazanavir ↑ beta-blockers; … |
| Ciclesonide | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Clarithromycin | drug interactions | Concomitant Drug Class/Specific Drugs: Antibacterials (macrolide or ketolide antibiotics): clarithromycin erythromycin telithromycin; … |
| Clonazepam | drug interactions | Concomitant Drug Class/Specific Drugs: Anticonvulsants that are metabolized by CYP3A (e.g., clonazepam); Effect b on Concentration: ↑ clonazepam; … |
| Clopidogrel | drug interactions | Concomitant Drug Class/Specific Drugs: clopidogrel; Effect b on Concentration: ↓ clopidogrel active metabolite; Clinical Comment: Coadministration with clopidogrel is not recommended due to the … |
| Clorazepate | drug interactions | Other Benzodiazepines: clorazepate diazepam estazolam flurazepam parente |
| Colchicine | contraindications | Drug Class: Antigout; Drugs within class that are contraindicated with EVOTAZ: colchicine (when used in patients with hepatic and/or renal impairment) |
| Cyclosporine | drug interactions | Concomitant Drug Class/Specific Drugs: Immunosuppressants: (e.g., cyclosporine, everolimus, sirolimus, tacrolimus); Effect b on Concentration: ↑ immunosuppressants; … |
| Dabigatran | drug interactions | Concomitant Drug Class/Specific Drugs: betrixaban dabigatran etexilate edoxaban; Effect b on Concentration: ↑ betrixaban ↑ dabigatran ↑ edoxaban; … |
| Dasatinib | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., dasatinib, nilotinib, vinblastine, vincristine); Effect b on Concentration: ↑ other anticancer agents; … |
| Desipramine | drug interactions | Concomitant Drug Class/Specific Drugs: Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, desipramine, imipramine, nortriptyline); Effect b on Concentration: ↑ TCAs |
| Dexamethasone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Diazepam | drug interactions | Other Benzodiazepines: clorazepate diazepam estazolam flurazepam parente |
| Digoxin | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Dihydroergotamine | contraindications | Drug Class: Ergot Derivatives; Drugs within class that are contraindicated with EVOTAZ: dihydroergotamine, ergotamine, methylergonovine |
| Diltiazem | drug interactions | Concomitant Drug Class/Specific Drugs: Calcium channel blockers: (e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil); Effect b on Concentration: ↑ calcium channel blocker; … |
| Disopyramide | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Dronedarone | contraindications | Drug Class: Antiarrhythmics; Drugs within class that are contraindicated with EVOTAZ: dronedarone |
| Drospirenone | contraindications | Drug Class: Hormonal Contraceptives; Drugs within class that are contraindicated with EVOTAZ: drospirenone/ethinyl estradiol |
| Edoxaban | drug interactions | Concomitant Drug Class/Specific Drugs: betrixaban dabigatran etexilate edoxaban; Effect b on Concentration: ↑ betrixaban ↑ dabigatran ↑ edoxaban; … |
| Efavirenz | drug interactions | Concomitant Drug Class/Specific Drugs: efavirenz; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↔ efavirenz; Clinical Comment: Coadministration of EVOTAZ with efavirenz is not recommended … |
| Elagolix | drug interactions | Concomitant Drug Class/Specific Drugs: Gonadotropin releasing hormone antagonist Receptor (GnRH): elagolix; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↑ elagolix; … |
| Elbasvir and grazoprevir | contraindications | For additional information, including clinical comments and potential impact on exposure levels associated with drugs that are contraindicated with EVOTAZ, refer to Table 5 [see Drug Interactions … |
| Encorafenib | contraindications | Drug Class: Antineoplastics; Drugs within class that are contraindicated with EVOTAZ: apalutamide, encorafenib, irinotecan, ivosidenib |
| Ergotamine | contraindications | Drug Class: Ergot Derivatives; Drugs within class that are contraindicated with EVOTAZ: dihydroergotamine, ergotamine, methylergonovine |
| Erythromycin | drug interactions | Concomitant Drug Class/Specific Drugs: Antibacterials (macrolide or ketolide antibiotics): clarithromycin erythromycin telithromycin; … |
| Eslicarbazepine | drug interactions | … Anticonvulsants with CYP3A induction effects that are NOT contraindicated (e.g., eslicarbazepine, oxcarbazepine); Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↓ atazanavir ↓ cobicistat; … |
| Estazolam | drug interactions | Other Benzodiazepines: clorazepate diazepam estazolam flurazepam parente |
| Etravirine | drug interactions | Concomitant Drug Class/Specific Drugs: etravirine; Effect b on Concentration: ↓ atazanavir ↓ cobicistat; Clinical Comment: Coadministration of EVOTAZ with etravirine is not recommended because it may … |
| Everolimus | drug interactions | Concomitant Drug Class/Specific Drugs: Immunosuppressants: (e.g., cyclosporine, everolimus, sirolimus, tacrolimus); Effect b on Concentration: ↑ immunosuppressants; … |
| Famotidine | drug interactions | Concomitant Drug Class/Specific Drugs: H 2 -Receptor antagonists (H 2 RA): (e.g., famotidine); Effect b on Concentration: ↓ atazanavir; … |
| Felodipine | drug interactions | Concomitant Drug Class/Specific Drugs: Calcium channel blockers: (e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil); Effect b on Concentration: ↑ calcium channel blocker; … |
| Fentanyl | drug interactions | Concomitant Drug Class/Specific Drugs: fentanyl; Effect b on Concentration: ↑ fentanyl; Clinical Comment: When EVOTAZ is coadministered with fentanyl, careful monitoring of therapeutic and adverse … |
| Flecainide | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Flurazepam | drug interactions | Other Benzodiazepines: clorazepate diazepam estazolam flurazepam parente |
| Fluticasone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Fluvastatin | drug interactions | Concomitant Drug Class/Specific Drugs: Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Effect b on Concentration: ↑ HMG-CoA reductase inhibitors; … |
| Fostamatinib | drug interactions | Concomitant Drug Class/Specific Drugs: Kinase inhibitors: fostamatinib; Effect b on Concentration: ↑ R406 active metabolite of fostamatinib; … |
| Glecaprevir and pibrentasvir | contraindications | For additional information, including clinical comments and potential impact on exposure levels associated with drugs that are contraindicated with EVOTAZ, refer to Table 5 [see Drug Interactions … |
| Imipramine | drug interactions | Concomitant Drug Class/Specific Drugs: Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, desipramine, imipramine, nortriptyline); Effect b on Concentration: ↑ TCAs |
| Irinotecan | contraindications | Drug Class: Antineoplastics; Drugs within class that are contraindicated with EVOTAZ: apalutamide, encorafenib, irinotecan, ivosidenib |
| Itraconazole | drug interactions | Concomitant Drug Class/Specific Drugs: Antifungals: ketoconazole, itraconazole; Effect b on Concentration: ↑ atazanavir ↑ cobicistat ↑ ketoconazole ↑ itraconazole; … |
| Ivosidenib | contraindications | Drug Class: Antineoplastics; Drugs within class that are contraindicated with EVOTAZ: apalutamide, encorafenib, irinotecan, ivosidenib |
| Ketoconazole | drug interactions | Concomitant Drug Class/Specific Drugs: Antifungals: ketoconazole, itraconazole; Effect b on Concentration: ↑ atazanavir ↑ cobicistat ↑ ketoconazole ↑ itraconazole; … |
| Lamotrigine | drug interactions | Other anticonvulsants (e.g., lamotrigine) lamotrigine: effects unknown Monitoring of lamotrigine concentrations is recommended with EVOTAZ coadministration. |
| Lidocaine | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Lomitapide | contraindications | Drug Class: Lipid-modifying Agents; Drugs within class that are contraindicated with EVOTAZ: lomitapide, lovastatin, simvastatin |
| Lovastatin | contraindications | Drug Class: Lipid-modifying Agents; Drugs within class that are contraindicated with EVOTAZ: lomitapide, lovastatin, simvastatin |
| Lurasidone | contraindications | Drug Class: Antipsychotics; Drugs within class that are contraindicated with EVOTAZ: lurasidone, pimozide |
| Maraviroc | drug interactions | Concomitant Drug Class/Specific Drugs: maraviroc; Effect b on Concentration: ↑ maraviroc; Clinical Comment: When coadministering maraviroc and EVOTAZ, patients should receive maraviroc 150 mg twice … |
| Methadone | drug interactions | A dose adjustment for buprenorphine, buprenorphine/naloxone or methadone may be needed. |
| Methylergonovine | contraindications | Drug Class: Ergot Derivatives; Drugs within class that are contraindicated with EVOTAZ: dihydroergotamine, ergotamine, methylergonovine |
| Methylprednisolone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Metoprolol | drug interactions | Concomitant Drug Class/Specific Drugs: Beta-Blockers: (e.g., metoprolol, carvedilol, timolol); Effect b on Concentration: ↔ atazanavir ↑ beta-blockers; … |
| Mexiletine | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Midazolam | contraindications | Drug Class: Sedative/hypnotics; Drugs within class that are contraindicated with EVOTAZ: triazolam, orally administered midazolam b |
| Mometasone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Naloxone | drug interactions | Concomitant Drug Class/Specific Drugs: Narcotic analgesics: For treatment of opioid dependence: buprenorphine, naloxone, methadone; … |
| Nevirapine | contraindications | Drug Class: Non-nucleoside Reverse Transcriptase Inhibitor; Drugs within class that are contraindicated with EVOTAZ: nevirapine |
| Nifedipine | drug interactions | Concomitant Drug Class/Specific Drugs: Calcium channel blockers: (e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil); Effect b on Concentration: ↑ calcium channel blocker; … |
| Nilotinib | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., dasatinib, nilotinib, vinblastine, vincristine); Effect b on Concentration: ↑ other anticancer agents; … |
| Nortriptyline | drug interactions | Concomitant Drug Class/Specific Drugs: Tricyclic Antidepressants (TCAs) (e.g., amitriptyline, desipramine, imipramine, nortriptyline); Effect b on Concentration: ↑ TCAs |
| Omeprazole | drug interactions | Concomitant Drug Class/Specific Drugs: Proton-pump inhibitors (PPI): (e.g., omeprazole); Effect b on Concentration: ↓ atazanavir; … |
| Oxcarbazepine | drug interactions | … induction effects that are NOT contraindicated (e.g., eslicarbazepine, oxcarbazepine); Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↓ atazanavir ↓ cobicistat; … |
| Paclitaxel | drug interactions | Use of EVOTAZ is not recommended when coadministered with drugs highly dependent on CYP2C8 for clearance with narrow therapeutic indices (e.g., paclitaxel, repaglinide) [see Clinical Pharmacology … |
| Paroxetine | drug interactions | Concomitant Drug Class/Specific Drugs: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g., paroxetine); Effect b on Concentration: SSRIs: effects unknown; … |
| Perphenazine | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., perphenazine, risperidone, thioridazine); Effect b on Concentration: ↑ antipsychotic; … |
| Phenobarbital | contraindications | Drug Class: Anticonvulsants; Drugs within class that are contraindicated with EVOTAZ: carbamazepine, phenobarbital, phenytoin |
| Phenytoin | contraindications | Drug Class: Anticonvulsants; Drugs within class that are contraindicated with EVOTAZ: carbamazepine, phenobarbital, phenytoin |
| Pimozide | contraindications | Drug Class: Antipsychotics; Drugs within class that are contraindicated with EVOTAZ: lurasidone, pimozide |
| Prasugrel | drug interactions | Concomitant Drug Class/Specific Drugs: prasugrel; Effect b on Concentration: ↔ prasugrel active metabolite; Clinical Comment: No dose adjustment is needed when prasugrel is coadministered with … |
| Pravastatin | drug interactions | Concomitant Drug Class/Specific Drugs: Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Effect b on Concentration: ↑ HMG-CoA reductase inhibitors; … |
| Prednisolone | drug interactions | Concomitant Drug Class/Specific Drugs: Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; … |
| Prednisone | drug interactions | … suppression. Alternative corticosteroids including beclomethasone, prednisone, and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) … |
| Propafenone | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Quetiapine | drug interactions | Concomitant Drug Class/Specific Drugs: quetiapine; Effect b on Concentration: ↑ quetiapine; Clinical Comment: Initiation of EVOTAZ in patients taking quetiapine: Consider alternative antiretroviral … |
| Quinidine | drug interactions | Concomitant Drug Class/Specific Drugs: amiodarone, quinidine lidocaine (systemic), disopyramide, flecainide mexiletine, propafenone digoxin; … |
| Ranolazine | contraindications | Drug Class: Antianginal; Drugs within class that are contraindicated with EVOTAZ: ranolazine |
| Repaglinide | drug interactions | … CYP2C8 for clearance with narrow therapeutic indices (e.g., paclitaxel, repaglinide) [see Clinical Pharmacology (12.3; |
| Rifabutin | drug interactions | Concomitant Drug Class/Specific Drugs: Antimycobacterials: Rifabutin; Effect b on Concentration: atazanavir: effect unknown cobicistat: effect unknown ↑ rifabutin; … |
| Rifampin | contraindications | Drug Class: Antimycobacterials; Drugs within class that are contraindicated with EVOTAZ: rifampin |
| Risperidone | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., perphenazine, risperidone, thioridazine); Effect b on Concentration: ↑ antipsychotic; … |
| Ritonavir | drug interactions | Concomitant Drug Class/Specific Drugs: ritonavir or products containing ritonavir; Effect b on Concentration: ↑ atazanavir; … |
| Rivaroxaban | drug interactions | Concomitant Drug Class/Specific Drugs: rivaroxaban; Effect b on Concentration: ↑ rivaroxaban; Clinical Comment: Coadministration of EVOTAZ and rivaroxaban is not recommended because it may lead to … |
| Rosuvastatin | drug interactions | Concomitant Drug Class/Specific Drugs: Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin; Effect b on Concentration: ↑ HMG-CoA reductase inhibitors; … |
| Salmeterol | drug interactions | Concomitant Drug Class/Specific Drugs: Beta-agonist (inhaled): salmeterol; Effect b on Concentration: ↑ salmeterol; Clinical Comment: Coadministration with salmeterol is not recommended due to an … |
| Sildenafil | contraindications | Drug Class: Phosphodiesterase-5 (PDE-5) Inhibitor; Drugs within class that are contraindicated with EVOTAZ: sildenafil a when administered for the treatment of pulmonary arterial hypertension |
| Simvastatin | contraindications | Drug Class: Lipid-modifying Agents; Drugs within class that are contraindicated with EVOTAZ: lomitapide, lovastatin, simvastatin |
| Sirolimus | drug interactions | Concomitant Drug Class/Specific Drugs: Immunosuppressants: (e.g., cyclosporine, everolimus, sirolimus, tacrolimus); Effect b on Concentration: ↑ immunosuppressants; … |
| Sofosbuvir and velpatasvir and voxilaprevir | drug interactions | Hepatitis C Antiviral Agents sofosbuvir/velpatasvir/ voxilaprevir ↑ voxilaprevir Coadministration with EVOTAZ is not recommended. |
| Tacrolimus | drug interactions | Concomitant Drug Class/Specific Drugs: Immunosuppressants: (e.g., cyclosporine, everolimus, sirolimus, tacrolimus); Effect b on Concentration: ↑ immunosuppressants; … |
| Tadalafil | drug interactions | Concomitant Drug Class/Specific Drugs: Phosphodiesterase-5 (PDE-5) inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect b on Concentration: ↑ PDE-5 inhibitors; … |
| Tenofovir disoproxil | drug interactions | Concomitant Drug Class/Specific Drugs: tenofovir disoproxil fumarate; Effect b on Concentration: ↓ atazanavir ↑ tenofovir; … |
| Thioridazine | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., perphenazine, risperidone, thioridazine); Effect b on Concentration: ↑ antipsychotic; … |
| Ticagrelor | drug interactions | Concomitant Drug Class/Specific Drugs: Antiplatelets: ticagrelor; Effect b on Concentration: ↑ ticagrelor; Clinical Comment: Coadministration with ticagrelor is not recommended due to the potential … |
| Timolol | drug interactions | Concomitant Drug Class/Specific Drugs: Beta-Blockers: (e.g., metoprolol, carvedilol, timolol); Effect b on Concentration: ↔ atazanavir ↑ beta-blockers; … |
| Tramadol | drug interactions | Concomitant Drug Class/Specific Drugs: tramadol; Effect b on Concentration: ↑ tramadol; Clinical Comment: When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed. |
| Trazodone | drug interactions | … unknown; Clinical Comment: When coadministering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, using the lowest feasible initial or maintenance … |
| Triamcinolone | drug interactions | … ciclesonide dexamethasone fluticasone methylprednisolone mometasone triamcinolone; Effect b on Concentration: ↓ atazanavir ↓ cobicistat ↑ corticosteroids; … |
| Triazolam | contraindications | Drug Class: Sedative/hypnotics; Drugs within class that are contraindicated with EVOTAZ: triazolam, orally administered midazolam b |
| Vardenafil | drug interactions | Concomitant Drug Class/Specific Drugs: Phosphodiesterase-5 (PDE-5) inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect b on Concentration: ↑ PDE-5 inhibitors; … |
| Verapamil | drug interactions | Concomitant Drug Class/Specific Drugs: Calcium channel blockers: (e.g., amlodipine, diltiazem, felodipine, nifedipine, and verapamil); Effect b on Concentration: ↑ calcium channel blocker; … |
| Vinblastine | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., dasatinib, nilotinib, vinblastine, vincristine); Effect b on Concentration: ↑ other anticancer agents; … |
| Vincristine | drug interactions | Concomitant Drug Class/Specific Drugs: (e.g., dasatinib, nilotinib, vinblastine, vincristine); Effect b on Concentration: ↑ other anticancer agents; … |
| Voriconazole | drug interactions | Concomitant Drug Class/Specific Drugs: voriconazole; Effect b on Concentration: effects unknown; Clinical Comment: Coadministration with voriconazole is not recommended unless the benefit/risk … |
| Warfarin | drug interactions | Refer to DOAC dosing instructions for coadministration with P-gp inhibitors in DOAC prescribing information. warfarin warfarin: effect unknown Monitor the International Normalized Ratio (INR) when … |
Source: FDA drug label (EVOTAZ), NDA206353 (Bristol), as published by E.R. Squibb & Sons, L.L.C., effective May 12, 2025 (SPL set 83db29d7-5d85-49d6-8cb6-740473365cf8), via openFDA; the full label on DailyMed
What do FAERS reports show for atazanavir and cobicistat?
The FDA Adverse Event Reporting System holds 245 reports that list atazanavir and cobicistat among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 16 are coded as a death and 23 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as atazanavir and cobicistat?
38 other medicines are given the same way (oral) and in the same FDA class as atazanavir and cobicistat or labeled mainly for the same use (HIV), the same class first. HIV lists all 47 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Darunavir | HIV | 13 labelers | $1.16 per tablet 600 mg tablet | No current entry |
| Ritonavir | HIV | 7 labelers | $0.607 per tablet 100 mg tablet | A presentation being discontinued |
| Lopinavir and ritonavir | HIV | 3 labelers | $4.46 per tablet 200-50 mg tablet | A presentation being discontinued |
| Fosamprenavir | HIV | 2 labelers | n/a | No current entry |
| Nelfinavir | HIV | none listed | n/a | No current entry |
| Emtricitabine and tenofovir disoproxil | HIV | 25 labelers | $0.529 per tablet 200-300 mg tablet | No current entry |
| Lamivudine | HIV | 14 labelers | $0.489 per tablet 150 mg tablet | No current entry |
| Tenofovir disoproxil | HIV | 15 labelers | $0.294 per tablet 300 mg tablet | No current entry |
Every medicine labeled for the same conditions as atazanavir and cobicistat
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to atazanavir and cobicistat
- 38 medicines for the same use
- Other cytochrome p450 3a inhibitors
- the pharmacologic class, with prices and generics
- Atazanavir and cobicistat side effects
- the label's list beside FAERS reports
- Atazanavir and cobicistat shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other